Treating 1,000 people with preventive aspirin for five years prevents 2.9 major cardiovascular events (nonfatal myocardial infarction, nonfatal stroke, or cardiovascular death) and causes 2.8 major bleeds, according to a meta-analysis.
Nine primary prevention trials compared results for aspirin alone for the primary prevention of cardiovascular disease, and reported data on myocardial infarction, stroke and cardiovascular deaths. Aspirin doses ranged from 100 mg every other day to 500 mg/d, and seven of them studied doses from 75 mg/d to 162.5 mg/d. No dose-dependent effects were noted, the researchers said. Results appeared in the July issue of the American Heart Journal.
A total of 2,029 major cardiovascular events occurred among 52,145 (3.86%) patients allocated to aspirin compared with 2,099 major cardiovascular events among 50,476 (4.16%) patients assigned to placebo or control. Over a mean follow-up of nearly 7 years, aspirin was Read more »
*This blog post was originally published at ACP Internist*